Arcuri Cataldo, Monarca Lorenzo, Ragonese Francesco, Mecca Carmen, Bruscoli Stefano, Giovagnoli Stefano, Donato Rosario, Bereshchenko Oxana, Fioretti Bernard, Costantino Ferdinando
Department of Experimental Medicine, Perugia Medical School, University of Perugia, Piazza Lucio Severi 1, 06132 Perugia, Italy.
Department of Chemistry, Biology and Biotechnologies, University of Perugia, Via Elce di Sotto 8, 06123 Perugia, Italy.
Nanomaterials (Basel). 2018 Oct 23;8(11):867. doi: 10.3390/nano8110867.
The synthesis of ultrasmall UiO-66 nanoparticles (NPs) with an average size of 25 nm, determined by X-ray powder diffraction and electron microscopies analysis, is reported. The NPs were stabilized in water by dialyzing the NP from the DMF used for the synthesis. DLS measurements confirmed the presence of particles of 100 nm, which are spherical aggregates of smaller particles of 20⁻30 nm size. The NP have a BET surface area of 700 m²/g with an external surface area of 300 m²/g. UiO-66_N (UiO-66 nanoparticles) were loaded with acridine orange as fluorescent probe. UV-vis spectroscopy analysis revealed no acridine loss after 48 h of agitation in simulated body fluid. The biocompatibility of UiO-66_N was evaluated in human glioblastoma (GBM) cell line U251, the most malignant (IV grade of WHO classification) among brain tumors. In U251 cells, UiO-66_N are inert since they do not alter the cell cycle, the viability, migration properties, and the expression of kinases involved in cancer cell growth. The internalization process was evident after a few hours of incubation. After 24 h, UiO-66_N@Acr (UiO-66_N loaded with acridine orange) were detectable around the nuclei of the cells. These data suggest that small UiO-66 are biocompatible NP and could represent a potential carrier for drug delivery in glioblastoma therapies.
据报道，通过X射线粉末衍射和电子显微镜分析确定，已合成平均尺寸为25 nm的超小UiO-66纳米颗粒（NPs）。通过将NP从合成所用的N，N-二甲基甲酰胺（DMF）中透析出来，使NPs在水中稳定。动态光散射（DLS）测量证实存在100 nm的颗粒，其为尺寸为20⁻30 nm的较小颗粒的球形聚集体。该NP的比表面积为700 m²/g，外表面积为300 m²/g。用吖啶橙作为荧光探针负载到UiO-66_N（UiO-66纳米颗粒）上。紫外可见光谱分析表明，在模拟体液中搅拌48小时后没有吖啶损失。在人胶质母细胞瘤（GBM）细胞系U251中评估了UiO-66_N的生物相容性，U251是脑肿瘤中最恶性的（WHO分类IV级）。在U251细胞中，UiO-66_N是惰性的，因为它们不会改变细胞周期、活力、迁移特性以及参与癌细胞生长的激酶的表达。孵育数小时后内化过程明显。24小时后，在细胞核周围可检测到UiO-66_N@Acr（负载吖啶橙的UiO-66_N）。这些数据表明，小的UiO-66是生物相容性NP，并且可能代表胶质母细胞瘤治疗中药物递送的潜在载体。
